

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

THE GROUP'S PRODUCT CEFOPERAZONE SODIUM AND SULBACTAM SODIUM FOR INJECTION PASSED THE CONSISTENCY EVALUATION

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that Cefoperazone Sodium and Sulbactam Sodium for Injection (specification: 2.0g) submitted by Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, a wholly-owned subsidiary of the Company, with the approval of China National Medical Products Administration, passed the consistency evaluation of quality and efficacy for generic drugs ("Consistency Evaluation").

Cefoperazone Sodium and Sulbactam Sodium for Injection is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity that can be used alone or in combination with other agents. When used as monotherapy, it is indicated for the treatment of respiratory tract infections, urinary tract infections, intra-abdominal infections, septicemia, meningitis, skin and soft-tissue infections, bone and joint infections and genital tract infections caused by susceptible bacteria. It provides significant therapeutic effects against a wide range of inflammatory conditions and infections caused by susceptible bacteria and can effectively control inflammation. Currently, Cefoperazone Sodium and Sulbactam Sodium for Injection has been listed in the Category B in the National Medical Insurance Drug List (2024 Edition).

This approval will further solidify the Company's leading position in the anti-infective field. In the future, the Company will continue to devote itself to the research and development of new products and the promotion of the Consistency Evaluation, which is expected to create greater values for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 26 November 2025

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.